Innovent Biologics (HK:1801) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Innovent Biologics announces the resignation of Dr. Kaixian Chen as an independent non-executive director, effective December 27, 2024, to focus on other professional commitments. Dr. Chen’s departure will also lead to changes in the composition of the company’s board committees, with Gary Zieziula stepping in as a new member of the Remuneration Committee. This leadership transition is part of Innovent’s ongoing efforts to align its governance structure with its strategic goals.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.
